US law firm O’Melveny & Myers represented UBS Securities and Piper Jaffray as joint book-running managers in the US$66 million follow-on public offering of NASDAQ-listed Sinovac Biotech in February. Sinovac received net proceeds of approximately US$62 million from the sale of 11.5 million common shares at US$5.75 per share, including 1.5 million common shares sold when the underwriters exercised their over-allotment option in full.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
